Is Pulmonx Corp (LUNG) overvalued? · rev $83.8M
Pulmonx Corp (LUNG) is a medical devices company listed on US.
This page asks whether Pulmonx Corp (LUNG) looks expensive on cached numbers — not a short thesis.
Latest reported LUNG revenue for 2024-12-31 was $83.8M. Net income was -$56.4M. Revenue was up 22.0% from 2023-12-31 to 2024-12-31. LUNG currently screens at market cap $111.9M.
LUNG currently screens at market cap $111.9M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next LUNG 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the LUNG stock page for the full model, not this heading.
Not investment advice.